110100100010000100000Concentration nggConcentration nggKey Tissue PMO QuantificationSkeletal muscle ID: 893861
Download Pdf The PPT/PDF document "efficacy from toxicity over multiple ite..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
1 efficacy from toxicity over multiple ite
efficacy from toxicity over multiple iterations Ðcreating the next generation of delivery peptidesNew series of modified peptidesIdentify leads & iterateScreening for1. Efficacy in vivo2. Biodistribution3. Safety!PepGen EDOsSafe & EffectiveOUR EDOs WERE DEVELOPED THROUGH A DATA-DRIVE DESIGN PROCESSA novel enhanced delivery oligonucleotide (EDO) therapeutic demonstrates considerable potential in treating Duchenne muscular dystrophy Dr Ashling Holland, Dr Smita Gunnoo, Sam Ching, Rachel Johnson, Calum Irwin, Dr Sonia Bracegirdle, Dr Caroline GodfreyPepGen:BioEscalator, Innovation Building, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, United KingdomAn exciting step-change in oligonucleotide delivery with thepotential to transform the course of disease in DMDSuperior skeletal & cardiac muscle penetrance and efficacy, allowing critical disease phenotypes to be addressedA rapid path to the clinic: PepGen is on track to initiate first-in-human studies in 2022 110100100010000100000Concentration (ng/g) Concentration (ng/g)Key Tissue PMO QuantificationSkeletal muscle